Discounted Cash Flow
Arrowhead Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $158.3k | $-81.7m | $-68.3m | -51614.6% | $-1.34 |
| 2017 | $31.4m (19736.5%) | $-34.4m (57.9%) | $-31.9m (53.3%) | -109.5% (99.8%) | $-0.47 (64.9%) |
| 2018 | $16.1m (-48.6%) | $-54.5m (-58.4%) | $-48.6m (-52.7%) | -337.3% (-208.2%) | $-0.65 (-38.3%) |
| 2019 | $168.8m (945.7%) | $68.0m (224.8%) | $161.0m (431.0%) | 40.3% (111.9%) | $0.72 (210.8%) |
| 2020 | $88.0m (-47.9%) | $-84.6m (-224.4%) | $-107.3m (-166.7%) | -96.1% (-338.6%) | $-0.84 (-216.7%) |
| 2021 | $138.3m (57.2%) | $-140.8m (-66.6%) | $147.7m (237.6%) | -101.9% (-6.0%) | $-1.36 (-61.9%) |
| 2022 | $243.2m (75.9%) | $-176.1m (-25.0%) | $-188.9m (-227.9%) | -72.4% (28.9%) | $-1.67 (-22.8%) |
| 2023 | $240.7m (-1.0%) | $-205.3m (-16.6%) | $-330.6m (-75.0%) | -85.3% (-17.8%) | $-1.92 (-15.0%) |
| 2024 | $3.6m (-98.5%) | $-599.5m (-192.0%) | $-604.3m (-82.8%) | -16882.4% (-19698.7%) | $-5.00 (-160.4%) |
| 2025 | $829.4m (23258.2%) | $-1.6m (99.7%) | $156.9m (126.0%) | -0.2% (100.0%) | $-0.01 (99.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.